Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VanEck Junior Gold Miners — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.58 (market cap $9.43B), while VanEck Junior Gold Miners trades at $119.39. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| BIO | GDXJ | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $356.25 | $156.19 |
52-Week Low | $241.71 | $71.22 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
GDXJ trades at $120.71, up 1.62% today, with a bullish technical trend from moving averages but overbought signals from RSI levels. The ETF faces mixed sentiment, with recent news highlighting institutional selling by Amundi and underperformance versus peers in 2026. Support lies near $116, with resistance at $121.
The outlook is cautious due to high RSI readings and bearish oscillators, suggesting potential near-term pullbacks. Risks include Federal Reserve policy impacts on gold prices and competitive pressures from larger miner ETFs. Institutional activity shows reduced positions, indicating tempered confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
